NCT04902261 2023-09-01
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
Changhai Hospital
Phase 2 Unknown
Clinical Trials
3 trialsNCT05681390 2023-06-09
Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Unknown
NCT05634564 2022-12-05
Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown